{"disease":{"id":"von-willebrand-disorder","name":"von Willebrand disorder","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"vonicog-alfa","indication_name":"von Willebrand disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vonvendi","generic_name":"VONICOG ALFA","company_name":"Baxalta US Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"minirin","indication_name":"von Willebrand disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minirin","company_name":"Hormozgan University of Medical Sciences","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"desmopressin","indication_name":"von Willebrand disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ddavp","generic_name":"DESMOPRESSIN","company_name":"Ferring Pharms Inc","drug_phase":"marketed","molecular_target":"Vasopressin V1b receptor","drug_class":"Factor VIII Activator","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"argipressin","indication_name":"von Willebrand disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Argipressin","company_name":"Kristina Svennerholm","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}